Global Gene Therapy for CNS Disorders Market Size, Status and Forecast 2019-2025

Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered
• 1.4 Market Analysis by Type
  • 1.4.1 Global Gene Therapy for CNS Disorders Market Size Growth Rate by Type (2014-2025)
  • 1.4.2 Ex Vivo
  • 1.4.3 In Vivo
• 1.5 Market by Application
  • 1.5.1 Global Gene Therapy for CNS Disorders Market Share by Application (2014-2025)
  • 1.5.2 Hospitals
  • 1.5.3 Clinics
  • 1.5.4 Others
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends

• 2.1 Gene Therapy for CNS Disorders Market Size
• 2.2 Gene Therapy for CNS Disorders Growth Trends by Regions
  • 2.2.1 Gene Therapy for CNS Disorders Market Size by Regions (2014-2025)
  • 2.2.2 Gene Therapy for CNS Disorders Market Share by Regions (2014-2019)
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Opportunities

3 Market Share by Key Players

• 3.1 Gene Therapy for CNS Disorders Market Size by Manufacturers
  • 3.1.1 Global Gene Therapy for CNS Disorders Revenue by Manufacturers (2014-2019)
  • 3.1.2 Global Gene Therapy for CNS Disorders Revenue Market Share by Manufacturers (2014-2019)
  • 3.1.3 Global Gene Therapy for CNS Disorders Market Concentration Ratio (CR5 and HHI)
• 3.2 Gene Therapy for CNS Disorders Key Players Head office and Area Served
• 3.3 Key Players Gene Therapy for CNS Disorders Product/Solution/Service
• 3.4 Date of Enter into Gene Therapy for CNS Disorders Market
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application

• 4.1 Global Gene Therapy for CNS Disorders Market Size by Type (2014-2019)
• 4.2 Global Gene Therapy for CNS Disorders Market Size by Application (2014-2019)

5 United States

• 5.1 United States Gene Therapy for CNS Disorders Market Size (2014-2019)
• 5.2 Gene Therapy for CNS Disorders Key Players in United States
• 5.3 United States Gene Therapy for CNS Disorders Market Size by Type
• 5.4 United States Gene Therapy for CNS Disorders Market Size by Application

6 Europe

• 6.1 Europe Gene Therapy for CNS Disorders Market Size (2014-2019)
• 6.2 Gene Therapy for CNS Disorders Key Players in Europe
• 6.3 Europe Gene Therapy for CNS Disorders Market Size by Type
• 6.4 Europe Gene Therapy for CNS Disorders Market Size by Application

7 China

• 7.1 China Gene Therapy for CNS Disorders Market Size (2014-2019)
• 7.2 Gene Therapy for CNS Disorders Key Players in China
• 7.3 China Gene Therapy for CNS Disorders Market Size by Type
• 7.4 China Gene Therapy for CNS Disorders Market Size by Application

8 Japan

• 8.1 Japan Gene Therapy for CNS Disorders Market Size (2014-2019)
• 8.2 Gene Therapy for CNS Disorders Key Players in Japan
• 8.3 Japan Gene Therapy for CNS Disorders Market Size by Type
• 8.4 Japan Gene Therapy for CNS Disorders Market Size by Application

9 Southeast Asia

• 9.1 Southeast Asia Gene Therapy for CNS Disorders Market Size (2014-2019)
• 9.2 Gene Therapy for CNS Disorders Key Players in Southeast Asia
• 9.3 Southeast Asia Gene Therapy for CNS Disorders Market Size by Type
• 9.4 Southeast Asia Gene Therapy for CNS Disorders Market Size by Application

10 India

• 10.1 India Gene Therapy for CNS Disorders Market Size (2014-2019)
• 10.2 Gene Therapy for CNS Disorders Key Players in India
• 10.3 India Gene Therapy for CNS Disorders Market Size by Type
• 10.4 India Gene Therapy for CNS Disorders Market Size by Application

11 Central & South America

• 11.1 Central & South America Gene Therapy for CNS Disorders Market Size (2014-2019)
• 11.2 Gene Therapy for CNS Disorders Key Players in Central & South America
• 11.3 Central & South America Gene Therapy for CNS Disorders Market Size by Type
• 11.4 Central & South America Gene Therapy for CNS Disorders Market Size by Application

12 International Players Profiles

• 12.1 Gilead (Kite Pharma)
  • 12.1.1 Gilead (Kite Pharma) Company Details
  • 12.1.2 Company Description and Business Overview
  • 12.1.3 Gene Therapy for CNS Disorders Introduction
  • 12.1.4 Gilead (Kite Pharma) Revenue in Gene Therapy for CNS Disorders Business (2014-2019)
  • 12.1.5 Gilead (Kite Pharma) Recent Development
• 12.2 Amgen (BioVex)
  • 12.2.1 Amgen (BioVex) Company Details
  • 12.2.2 Company Description and Business Overview
  • 12.2.3 Gene Therapy for CNS Disorders Introduction
  • 12.2.4 Amgen (BioVex) Revenue in Gene Therapy for CNS Disorders Business (2014-2019)
  • 12.2.5 Amgen (BioVex) Recent Development
• 12.3 Novartis
  • 12.3.1 Novartis Company Details
  • 12.3.2 Company Description and Business Overview
  • 12.3.3 Gene Therapy for CNS Disorders Introduction
  • 12.3.4 Novartis Revenue in Gene Therapy for CNS Disorders Business (2014-2019)
  • 12.3.5 Novartis Recent Development
• 12.4 Roche (Spark Therapeutics)
  • 12.4.1 Roche (Spark Therapeutics) Company Details
  • 12.4.2 Company Description and Business Overview
  • 12.4.3 Gene Therapy for CNS Disorders Introduction
  • 12.4.4 Roche (Spark Therapeutics) Revenue in Gene Therapy for CNS Disorders Business (2014-2019)
  • 12.4.5 Roche (Spark Therapeutics) Recent Development
• 12.5 Bluebird Bio
  • 12.5.1 Bluebird Bio Company Details
  • 12.5.2 Company Description and Business Overview
  • 12.5.3 Gene Therapy for CNS Disorders Introduction
  • 12.5.4 Bluebird Bio Revenue in Gene Therapy for CNS Disorders Business (2014-2019)
  • 12.5.5 Bluebird Bio Recent Development

13 Market Forecast 2019-2025

• 13.1 Market Size Forecast by Regions
• 13.2 United States
• 13.3 Europe
• 13.4 China
• 13.5 Japan
• 13.6 Southeast Asia
• 13.7 India
• 13.8 Central & South America
• 13.9 Market Size Forecast by Product (2019-2025)
• 13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
    • 15.1.1.1 Research Programs/Design
    • 15.1.1.2 Market Size Estimation
    • 12.1.1.3 Market Breakdown and Data Triangulation
  • 15.1.2 Data Source
    • 15.1.2.1 Secondary Sources
    • 15.1.2.2 Primary Sources
• 15.2 Disclaimer